The U.S. Food and Drug Administration (FDA) revised the boxed warning on the label for Tofacitinib (Xeljanz, Xeljanz XR) effective 2026-07-23. This revision highlights increased risks of serious infections, mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis for patients treated with the drug.
Background
Tofacitinib is a prescription medication with a previously established boxed warning. The latest revision, effective 2026-07-23, specifically updates the warning to include: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS. The warning further clarifies that patients treated with tofacitinib tablets are at increased risk for developing serious bacterial, fungal, and viral infections.
What this means
The updated boxed warning for Tofacitinib carries significant implications for prescribing practices and patient counseling. Healthcare providers must now give even greater consideration to the comprehensive risk profile, which now more explicitly includes mortality, major adverse cardiovascular events (MACE), and thrombosis, in addition to serious infections and malignancy. This necessitates thorough patient evaluation, careful risk-benefit assessment, and vigilant monitoring for these specific adverse events. For patients and patient advocates, this revision underscores the importance of understanding these heightened risks and engaging in detailed discussions with their healthcare team about the most appropriate treatment options and safety precautions.
Source
This information was sourced from the FDA, detailing a label revision for Tofacitinib effective 2026-07-23. The full details of the revised label are available on dailymed.nlm.nih.gov.